Toronto, State/Province — October 2, 2025 — Leads & Copy — Rockcliffe Labs Inc. has announced the launch of a $75 million non-brokered private placement in Canada at $10.00 per common share. The offering reflects a post-money valuation of approximately $300 million and is structured as the development financing contemplated under Rockcliffe Labs’ license term sheet with a Canadian university.
As part of that license, the Canadian university will hold a 7.5% equity interest in Rockcliffe Labs, equal to approximately 2.25 million shares valued at $22.5 million at the offering price. The company is structured as a biotechnology venture creation platform, designed to integrate Canadian academic research with the clinical, regulatory, and commercialization expertise required to bring therapies to market.
The lead program licensed from a Canadian university is a late-stage biomarker–based candidate for sepsis. Rockcliffe Labs intends to advance the program toward Phase 3 clinical trials in Canada within twelve (12) months of execution of the definitive license agreement, with a parallel U.S. regulatory path prepared if required.
Proceeds from the offering will be allocated to advancing the sepsis biomarker–based program to Phase 3 readiness in Canada, expanding regulatory engagement with Health Canada, building the infrastructure required to support clinical development and commercialization, and growing Rockcliffe Labs’ venture creation platform.
Rockcliffe Labs develops multi-asset pipelines across pharmaceuticals, diagnostics, and bio-based technologies.
Media Contact: media@rockcliffelabs.com
Investor Contact: ir@rockcliffelabs.com
Source: Rockcliffe Labs Inc.
